)
Visual
test
Akari Therapeutics
Akari Therapeutics (AKTX) investor relations material
Akari Therapeutics Proxy Filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Proxy Filing summary2 Feb, 2026
Executive summary
A general meeting is scheduled for March 2, 2026, to vote on five resolutions related to the exercisability of various warrants and the issuance of underlying shares, all in compliance with Nasdaq Listing Rules 5635(c) and 5635(d).
The warrants were issued in connection with a registered direct offering, a private placement, and a note exchange that closed in December 2025 and January 2026.
Approval of these proposals is required for the company to realize up to $8.9 million in potential gross proceeds from warrant exercises.
Failure to approve would prevent the exercise of these warrants and could result in additional costs and repeated shareholder meetings.
Voting matters and shareholder proposals
Five ordinary resolutions seek approval for the exercisability of Series G, Pre-Funded, Note Exchange, and Placement Agent Warrants, and the issuance of shares upon exercise.
All resolutions are recommended by the board and require a majority vote, with abstentions and broker non-votes not affecting the outcome.
Shareholders and ADS holders have detailed instructions for voting, including deadlines and proxy procedures.
Shareholders representing at least 5% of shares can call a general meeting or propose resolutions for the 2026 AGM.
Board of directors and corporate governance
The board unanimously recommends voting in favor of all resolutions, stating they are in the best interests of the company and shareholders.
The board is responsible for calling meetings and ensuring compliance with UK Companies Act and Nasdaq rules.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- SANSERA
Q1 FY25 delivered double-digit growth, margin expansion, and a record order book despite global headwinds. - JKHY
Record revenue, margin, and EPS growth drive raised guidance and strong segment momentum. - IEX
Record HST-driven growth and margin gains support 2026 outlook amid industrial headwinds. - KREF
Net loss for 2025, but strong liquidity, portfolio repositioning, and active capital management. - ODFL
Q4 revenue and earnings declined, but yield, service, and capital returns remained strong. - ORN
Acquisition expands marine construction scale and reach, supporting long-term profitable growth. - THG
Record earnings, improved underwriting, and strong capital actions drive robust 2025 results. - BAM
Record earnings, 15% dividend increase, and major AI initiatives drive robust growth. - LLY
Q4 2025 revenue up 43% to $19.3B; 2026 guidance: $80–$83B revenue, $33.50–$35 EPS. - CDW
2025 sales and profits rose, with strong cash returns and 2026 growth set to outpace the market.
Next Akari Therapeutics earnings date
Q4 202530 Mar, 2026
Akari Therapeutics
Next Akari Therapeutics earnings date
Q4 202530 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Akari Therapeutics PLC is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune and inflammatory diseases. The company’s research primarily targets conditions involving the complement and leukotriene pathways, which play key roles in immune system regulation. Akari Therapeutics is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage